Moderna, Inc. (NASDAQ:MRNA) shares are trending on Thursday night.
Shares of the Massachusetts-based biotechnology and pharmaceutical company edged 0.087% higher to $194.99 in after-hours trading on Thursday.
In the regular session, MRNA stock jumped 6.98% to close at $194.82, according to Benzinga Pro data.
Trial Data Takes Center Stage
The stock was seen moving after Moderna announced earlier this week that three abstracts on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, were accepted for presentation at the European Society for Medical Oncology Congress 2026 in Madrid. The congress is scheduled for Oct. 23 to 27.
The lead abstract, part of the Presidential Symposium, covers Phase 3 trial INTerpath-001, evaluating intismeran plus Merck & Co.‘s (NYSE:MRK) pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma patients. Two additional poster presentations will detail data in pancreatic and early-stage non-small cell lung cancer.
Trading Metrics, Technical Analysis
Moderna has a market capitalization of $77.78 billion, a 52-week high of $195.71 and a 52-week low of $22.29.
The Relative Strength Index (RSI) of MRNA stands at 75.12.
The large-cap biotech stock has gained 655.41% over the past 12 months.
MRNA is currently positioned close to its annual high.
With a strong Momentum in the 99th percentile, Benzinga’s Edge Stock Rankings indicate that Moderna stock has a positive price trend across all time frames.
See More: Top Value Stocks
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Tada Images / Shutterstock
Login to comment